CompletedNot Applicable

Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

Iran296 participantsStarted 2020-08-04

Plain-language summary

The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia. The main questions are aim to answer: 1. Is Rhofanib® (Tofacitinib) safe in Alopecia? 2. Is Rhofanib® (Tofacitinib) work to treat Alopecia? In this study, there is no comparison group. Participants received Rhofanib® (Tofacitinib) with or without adjuvant prednisolone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female with the age of 18 years or older * Clinical diagnosis of alopecia areata with at least 40% scalp hair loss, alopecia totalis, or alopecia universalis who are prescribed Rhofanib® * Stable or worsening disease for at least 6 months * Patients who have given written authorization to use their personal health data for the purpose of this study.

What they're measuring

Safety assessment

Timeframe: Study period ( Up to 6 months)

Trial details

NCT IDNCT07101471

SponsorNanoAlvand

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-06-11

View on ClinicalTrials.gov More Alopecia Totalis/Universalis trials